News

11 April 2017

Vantia Therapeutics Completes Enrollment in the EQUINOC® Study, a Pivotal Study with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia.


9 May 2016

Vantia Therapeutics Publishes The Nocturia Patient Reported Outcome Instrument, Nocturia Treatment Impact Measure, NocTIMe, at the American Urological Association Meeting in San Diego, 2016.


21 March 2017

Vantia Therapeutics Initiates the EQUINOC® Study, a Pivotal Study with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia.


6 July 2011

Vantia today announced that it has raised £4 Million ($6.5 million) to fund clinical development of its lead compounds.


9 June 2010

Vantia today announced that it has appointed Andrew Crockett to the position of Chief Executive Officer (CEO).


26 March 2010

Vantia reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913, at the ACS National Meeting in San Francisco, USA.


2 February 2010

Vantia's lead candidate VA106483 enters Phase IIb trial for nocturia.


7 December 2009

Vantia is listed in the British Venture Capital Association's HOT Talent Handbook, a rollcall of some of Britain's most exciting young companies and a celebration of the best and the brightest plying their trade in the pursuit of invention and innovation.


6 October 2009

Vantia's lead candidate VA111913 enters Phase II proof-of-concept trial in dysmenorrhoea.


26 August 2009

Vantia appoints Andrew Crockett as Vice President Business Development.


29 June 2009

Vantia's lead candidate VA106483 demonstrates positive anti-diuretic effect in Phase IIa trial in nocturia.


21 April 2009

Vantia appoints Rachel Morten as Head of Regulatory Affairs.


24 March 2009

Vantia's pipeline continues to mature - VA106483 completes Phase IIa trial and VA111913 completes Phase I dosing.


26 November 2008

Jim Phillips, CEO of Vantia Ltd, talks to BioCentury about Vantia's rapid progress.


3 November 2008

Vantia progresses clinical development of its lead drug candidates - VA106483 starts Phase II and VA111913 enters clinic, VA118020 in preclinical development.


20 October 2008

An article titled "Could this pill cure the agony of severe period pains?", describing the symptoms of dysmenorrhoea and Vantia's clinical trial of VA111913, appeared in Daily Mail Online.


19 March 2008

New UK R&D company Vantia, launched with backing from MVM Life Science Partners, SV Life Sciences and Novo A/S.






Adobe Reader may be required to view PDF files - if you need to install Adobe Reader please click here.